The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands.

BACKGROUND

The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted.

OBJECTIVE

To evaluate the impact of the COVID-19 outbreak on bladder cancer care in the Netherlands.

METHODS

The number of bladder cancer (BC) diagnoses per month during 2020-2021 was compared to 2018-2019 based on preliminary data from the Netherlands Cancer Registry (NCR). Additionally, detailed data were retrieved from the NCR for the cohort diagnosed between March 1

RESULTS

During the first COVID wave (week 9-22), the number of BC diagnoses decreased by 14%, corresponding with approximately 300 diagnoses, but increased again in the second half of 2020. The decline was most pronounced from week 13 onwards in patients≥70 years and patients with non-muscle invasive BC. Patients with muscle-invasive disease were less likely to undergo a radical cystectomy (RC) in week 17-22 (OR = 0.62, 95% CI = 0.40-0.97). Shortly after the start of the outbreak, use of neoadjuvant chemotherapy decreased from 34% to 25% but this (non-significant) effect disappeared at the end of April. During the first wave, 5% more RCs were performed compared to previous years. Time from diagnosis to RC became 6 days shorter. Overall, a 7% reduction in RCs was observed in 2020.

CONCLUSIONS

The number of BC diagnoses decreased steeply by 14% during the first COVID wave but increased again to pre-COVID levels by the end of 2020 (i.e. 600 diagnoses/month). Treatment-related changes remained limited and followed the adapted guidelines. Surgical volume was not compromised during the first wave. Altogether, the impact of the first COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less pronounced than was reported for other solid tumors, both in the Netherlands and abroad. However, its impact on bladder cancer stage shift and long-term outcomes, as well as later pandemic waves remain so far unexamined.

Informations de copyright

© 2022 – The authors. Published by IOS Press.

Déclaration de conflit d'intérêts

Lambertus A. Kiemeney and J. Alfred Witjes are Editorial Board members of this journal, but were not involved in the peer-review process nor had access to any information regarding its peer-review. Lisa M.C. van Hoogstraten, Richard P. Meijer, Geert J.L.H. van Leenders, Ben G.L. Vanneste, Luca Incrocci, Tineke J. Smilde, Sabine Siesling, Katja K.H. Aben, the BlaZIB study group and the COVID and Cancer-NL consortium declare that they have no conflict of interest.